Bexion Pharmaceuticals, LLC
is doing amazing things in the fight against pancreatic cancer, and the Kentucky Cabinet for Economic Development
(KCED) is taking notice.
In an effort to help this pancreatic cancer research along, the KCED has awarded SBIR-STTR matching funds of $99,965 to Bexion for their National Institutes of Health
(NIH) grant called "A Novel Biotherapeutic Treatment for Pancreatic Cancer."
In addition to the KCED, Northern Kentucky ezone, a division of Northern Kentucky Tri-County Economic Development Corporation
(Tri-ED) and the KCED's Department of Commercialization (DCI) are also lending a helping hand to Bexion.
"Northern Kentucky is in the early stages of becoming a significant contributor to Kentucky’s future in the field of bioscience with Bexion’s presence and the additional companies that will come to the area as a result of this company’s success," says Chairman of NKY Tri-ED and Kenton County Judge Executive, Ralph Drees.
Bexion is gaining notoriety for a promising piece of preclinical anti-tumor technology from Cincinnati Children's Hospital Medical Center
This new protein-lipid nanovesicle technology attacks tumors in cases of glioma, pancreatic cancer, neuroblastoma and leukemia, and selectively kills cancer cells, while leaving healthy cells unscathed.
In addition to being a boon for cancer victims, this new technology holds great promise for Northern Kentucky's flourishing medical research industry.
"Bexion is a very promising addition to Northern Kentucky’s growing and emerging life science portfolio of companies," says DCI Commissioner Deborah Clayton. "The Commonwealth’s unique SBIR-STTR matching program is a valuable resource available to high-tech companies located in the state or willing to relocate here."
KCED's assistance to Bexion has been received with gratitude.
In a clear statement of appreciation, Bexion CEO Dr. Ray Takigiku says, "Bexion’s mission is to develop cures for cancer, and Northern Kentucky’s programs are helping us by providing a much needed mechanism to increase our resources to more rapidly bring our first product into the clinic and help patients… These Northern Kentucky programs clearly support us."
Writer: Jonathan DeHart
Source: Cheryl Besl, Kentucky Cabinet for Economic Development, Bexion Pharmaceuticals, LLC